In a significant strategic move to enhance its international footprint, Caplin Point Laboratories Ltd., through its wholly-owned Hong Kong-based subsidiary Caplin Point Far East Ltd., has announced the acquisition of Mexico-based Triwin Pharma. This decision aligns with the company’s broader goal of deepening its presence in Latin American pharmaceutical markets, which have been a stronghold for Caplin Point in recent years.

The Deal: Acquisition of Triwin Pharma by Caplin Point Far East

On June 4, 2025, Caplin Point Laboratories informed the stock exchanges that Caplin Point Far East Ltd. executed a share purchase agreement on June 3 to acquire 100% stake in Triwin Pharma, a company incorporated in Mexico on February 12, 2019. The current share capital of Triwin comprises 50,000 equity shares of one Mexican peso each, and it has reported no turnover in the last three years, including the year ending March 31, 2025.

Upon completion, Triwin Pharma will become a wholly-owned subsidiary of Caplin Point Far East and a step-down subsidiary of Caplin Point Laboratories.

Strategic Rationale Behind the Acquisition

Why would Caplin Point acquire a company with no turnover? According to the official exchange filing, the acquisition was a calculated strategic decision to establish a local entity in Mexico—a move that enables:

• Participation in local government tenders,

• Establishment of stock-and-sale operations, and

• Direct sales, marketing, and distribution of pharmaceutical products.

These benefits mirror Caplin Point’s existing successful operations across other Latin American markets, where having local presence and regulatory eligibility enables faster market access and competitive participation in public healthcare procurement.

Role of Triwin Pharma Post Acquisition

Once the acquisition is completed, Triwin Pharma will serve as the front-end entity for Caplin Point’s operations in Mexico, enabling:

• Direct engagement with distributors and healthcare institutions

• Participation in the national tender process

• Marketing and distribution of drugs manufactured by Caplin Point and its subsidiaries

This model ensures localized control, faster regulatory approval, and smoother distribution—a necessity in highly regulated Latin American pharmaceutical markets.

Acquisition Details and Timeline

The agreement was executed on June 3, 2025, and Caplin Point Far East is expected to complete the acquisition within 30 days by paying the consideration via normal banking channels. While the transaction value remains undisclosed, the mode of payment ensures transparency and regulatory compliance in international transactions.

The company also confirmed that Triwin Pharma will be considered a related party upon completion of the acquisition, given its status as a subsidiary.

Financial Snapshot of Triwin Pharma

• Incorporation Date: February 12, 2019

• Registered Capital: 50,000 equity shares of one Mexican peso each

• Turnover (FY ending March 2025): NIL

• Turnover (past 3 years): NIL

Despite these numbers, Caplin Point has emphasised the strategic value of Triwin as an enabler of market entry rather than immediate financial returns.

Caplin Point’s Latin American Playbook

This acquisition is not Caplin Point’s first foray into Latin America. The company has previously implemented a stock-and-sale model successfully in several Latin American countries. The model includes:

• Establishing local legal entities

• Holding product inventory within the country

• Participating in public procurement tenders

• Leveraging on-ground sales and distribution teams

This approach has allowed Caplin Point to generate sustainable revenue streams from these regions, despite currency volatility and regional healthcare reforms.

By replicating this model in Mexico, the second-largest pharmaceutical market in Latin America, Caplin Point positions itself to tap into public healthcare programs and B2B opportunities.

Market Reaction and Share Performance

Following the announcement, Caplin Point’s stock was trading 0.3% lower at ₹2,161.7. However, the stock has seen a 14% gain in the past month, reflecting positive investor sentiment towards the company’s international growth strategy.

Why Mexico?

Mexico is a key player in the Latin American pharmaceutical landscape, offering:

• A large population with growing healthcare needs

• Government procurement programs for essential medicines

• A strategic location with trade ties to both North and South America

• Regulatory mechanisms that favour local entities for participation in tenders

With Caplin Point's product basket catering to injectables and hospital supplies, a presence in Mexico offers access to bulk procurement programs and hospital networks.

Long-Term Outlook

This acquisition reflects Caplin Point’s long-term vision of global expansion through strategic partnerships and acquisitions. The company’s entry into Mexico, through Triwin Pharma, is expected to yield:

• Improved revenue visibility in Latin America

• Expansion of product access and reach

• Operational synergies with existing logistics and manufacturing capabilities

Caplin Point also aims to strengthen its pharmacovigilance systems, supply chain capabilities, and regulatory teams in these markets to ensure smooth integration and sustainable performance.

Conclusion

Caplin Point Laboratories’ acquisition of Triwin Pharma is a pivotal move in expanding its footprint in Latin America, with Mexico acting as a gateway market. While Triwin Pharma currently has no turnover, its strategic position, regulatory potential, and market access capability make it a valuable asset.

This acquisition is not merely about numbers—it’s about unlocking a market with long-term potential, replicating a proven model, and establishing Caplin Point as a key player in the Latin American pharmaceutical sector.

The Upcoming IPOs in this week and coming weeks are Jainik Power Cables, Sacheerome Limited, Victory Electric Vehicles International, Wagons Learning.

The Current active IPO are Ganga Bath Fittings.

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst.